ORPHA:300557
Carcinoma of the ampulla of Vater
Also known as: Ampulloma · Ampullary carcinoma
Publications
3,144
89.5th percentile
Trials
9
Interventional, condition-specific
Researchers
1,443
Distinct authors in sample
Gene link
—
Readiness
2/6
Stages with a signal
Clinical definition (Orphanet)
Carcinoma of the ampulla of Vater is a rare malignant tumor originating from the ampulla of Vater that can present with symptoms of general fatigue, loss of appetite, weight loss, nausea, vomiting, abdominal pain and, most commonly, painless obstructive jaundice. The tumor is believed to arise from duodenal, biliary or pancreatic epilthelium, resulting in the respective histological types. In general, carcinoma of the ampulla of Vater has a better prognosis (5-year survival rate of 45%) than cancers of the distal bile duct and pancreas.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0017590
- UMLS:C0262401
- NCIT:C3908
Additional Mondo synonyms (5)
ampulla of Vater carcinoma · ampullary carcinoma · carcinoma of ampulla of vater · carcinoma of hepatopancreatic ampulla · hepatopancreatic ampulla carcinoma
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
2/6 stages with a signal
An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
3,144 matched papers (1,553 in last 10 years) Source
- Phenotype characterisedNot found
No HPO disease–phenotype associations via Monarch for these Mondo IDs
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPresent
9 matched on ClinicalTrials.gov (5 recruiting in sample)
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
None returned for this Mondo ID. That often means “not linked under this ID,” not “no clinical features.”
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
12
Drugs / clinical candidates · MONDO_0017590
- CISPLATIN·phase 3
- FLUOROURACIL·phase 3
- FOSGEMCITABINE PALABENAMIDE·phase 3
- GEMCITABINE·phase 3
- LEUCOVORIN·phase 3
- OXALIPLATIN·phase 3
- CETUXIMAB·phase 2
- RETIFANLIMAB·phase 2
- ERLOTINIB HYDROCHLORIDE·phase 1
- GEMCITABINE HYDROCHLORIDE·phase 1
- IRINOTECAN·phase 1 2
- PACLITAXEL·phase 1 2
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
3,144
3,144 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
3,144 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
1,553 in the last 10 years · high confidence · 89.5th percentile (publications denominator)
Phrase hits: 3,144 · MeSH hits: 0
Who's working on it?
1,443
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.
- 01Suzuki Y7 papers · 2026
Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Papers in Europe PMC - 02Liu Y5 papers · 2026
School of Pharmacy, Lanzhou University, No. 199 Donggang West Road, Lanzhou 730000, PR China. Electronic address: yqliu@lzu.edu.cn.
Papers in Europe PMC - 03Maeda S5 papers · 2026
Department of Gastroenterology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Papers in Europe PMC - 04Ashida R4 papers · 2024
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Papers in Europe PMC - 05Endo K4 papers · 2026
Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Papers in Europe PMC - 06Kobayashi T4 papers · 2026
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine, 7-5-2 Kusunoki-cho, Chuo-ku, Kobe, Hyogo, 650-0017, Japan.
Papers in Europe PMC - 07Liu J4 papers · 2026
Division of Gastroenterology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, 1277 Jiefang Avenue, 430022, Wuhan, China.
Papers in Europe PMC - 08Miwa H4 papers · 2026
Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Papers in Europe PMC - 09Ohgi K4 papers · 2024
Division of Hepato-Biliary-Pancreatic Surgery, Shizuoka Cancer Center, Shizuoka, Japan.
Papers in Europe PMC - 10Oishi R4 papers · 2026
Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan.
Papers in Europe PMC
Clinical research
Is a treatment being tested?
9
interventional trials for this specific condition
9 interventional trials matched this specific condition name; 5 currently recruiting in our sample.
Data as of 11 September 2026
9 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 92th percentile).
high confidence · 92th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
9 interventional trials matched after quoted-phrase search and title/condition post-filter.
- NCT06333314·RECRUITING·Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI
Not reviewed·Conditions: Pancreatic Adenocarcinoma · Ampulla of Vater Carcinoma · Adrenocortical Carcinoma · Neuroendocrine Carcinoma·Matched via name phrase
- NCT06062485·NOT YET RECRUITING·Surufatinib Combined With Toripalimab and AG Regiments for First-line Treatment of Unresectable or Relapsing Metastatic Ampullary Carcinoma
Not reviewed·Conditions: Ampullary Carcinoma·Matched via name phrase
- NCT07328607·RECRUITING·Outcomes After Laparoscopic Versus Open Pancreaticoduodenectomy
Not reviewed·Conditions: Pancreatic Ductal Adenocarcinoma · Ampullary Carcinoma · Distal Cholangiocarcinoma · Duodenal Adenocarcinoma·Matched via name phrase
- NCT07446543·NOT YET RECRUITING·Effect of Negative-Pressure Drainage Versus Pancreatic Duct Stenting for Preventing Pancreatitis After Endoscopic Papillectomy for Duodenal Papillary Tumors
Not reviewed·Conditions: Ampulla of Vater Neoplasms · Ampullary Adenoma · Ampullary Carcinoma·Matched via name phrase
- NCT07283939·RECRUITING·Studying the PAGODA Algorithm for Chemotherapy Dose Changes to Prevent Unplanned Treatment Delays
Not reviewed·Conditions: Ampulla of Vater Carcinoma · Appendix Carcinoma · Carcinoma of Unknown Primary With Gastrointestinal Profile · Colon Carcinoma·Matched via name phrase
Observational and natural-history studies
2 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.
None of the matched observational studies is currently listed as recruiting.
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 2 · after dedupe 2 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 2 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Uncertain / not reviewed (2)
- isrctn·ISRCTN73941125·No longer recruiting·A randomised trial comparing epirubicin, cisplatin and protracted venous infusion (PVI) 5-Fluorouracil (5FU) (ECF) to 5FU, Etoposide Leucovorin (FELU) in patients with inoperable or metastatic biliary cancer
skipped — LLM skipped (--skip-llm)
- isrctn·ISRCTN21587955·No longer recruiting·Randomised trial of adjuvant therapy in operable pancreatic cancer
skipped — LLM skipped (--skip-llm)
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for Carcinoma of the ampulla of Vater — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Carcinoma of the ampulla of Vater" OR "Carcinoma of ampulla of Vater" OR "Ampulloma" OR "Ampullary carcinoma" OR "ampulla of Vater carcinoma" OR "ampulla of the Vater carcinoma" OR "carcinoma of the ampulla of the vater" OR "carcinoma of hepatopancreatic ampulla" OR "carcinoma of the hepatopancreatic ampulla" OR "hepatopancreatic ampulla carcinoma"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Carcinoma of the ampulla of Vater" OR "Carcinoma of ampulla of Vater" OR "Ampulloma" OR "Ampullary carcinoma" OR "ampulla of Vater carcinoma" OR "ampulla of the Vater carcinoma" OR "carcinoma of the ampulla of the vater" OR "carcinoma of hepatopancreatic ampulla" OR "carcinoma of the hepatopancreatic ampulla" OR "hepatopancreatic ampulla carcinoma"
Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).
Study-type breakdown: 9 interventional · 2 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T12:42:11.984Z
